Siegfried Barbera, SL is recalling approximately 2,016 bottles of Votrient (pazopanib) 200 mg tablets because the product failed dissolution testing. This medication, distributed by Novartis Pharmaceuticals Corp., is packaged in 120-count bottles. This defect means the tablets may not break down correctly in the body, which could potentially interfere with how the medication is absorbed. No incidents or injuries have been reported to date.
If the tablets fail to dissolve as specified, the patient may not receive the full intended dose of the medication, which could reduce its effectiveness in treating the underlying condition.
You have 2 options:
Distributed by Novartis Pharmaceuticals Corp.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.